July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A new ophthalmic pharmaceutical formulation, topical sulglycotide enhances the ocular mucin secretion in the desiccation stress-mediated dry eye disease
Author Affiliations & Notes
  • Hyesook Lee
    T2B infrastructure center for ocular diseases, Inje University Busan Paik Hospital, Busan, Korea (the Republic of)
  • Sangwon Jeon
    College of Pharmacy, Ajou University, Suwon City, Korea (the Republic of)
  • Chae Eun Kim
    T2B infrastructure center for ocular diseases, Inje University Busan Paik Hospital, Busan, Korea (the Republic of)
    Department of Ophthalmology, Inje University College of Medicine, Busan, Korea (the Republic of)
  • Yoonjin Lee
    T2B infrastructure center for ocular diseases, Inje University Busan Paik Hospital, Busan, Korea (the Republic of)
  • Young-Joon Park
    College of Pharmacy, Ajou University, Suwon City, Korea (the Republic of)
  • JaeWook Yang
    T2B infrastructure center for ocular diseases, Inje University Busan Paik Hospital, Busan, Korea (the Republic of)
    Department of Ophthalmology, Inje University College of Medicine, Busan, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Hyesook Lee, None; Sangwon Jeon, None; Chae Eun Kim, None; Yoonjin Lee, None; Young-Joon Park, None; JaeWook Yang, None
  • Footnotes
    Support  This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare Affairs, Republic of Korea (grant #: HI15C1142)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3832. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hyesook Lee, Sangwon Jeon, Chae Eun Kim, Yoonjin Lee, Young-Joon Park, JaeWook Yang; A new ophthalmic pharmaceutical formulation, topical sulglycotide enhances the ocular mucin secretion in the desiccation stress-mediated dry eye disease. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3832.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Sulglycotide (SOS), a polysulphated glycopeptide derived from porcine duodenal mucin and unabsorbable from the gastrointestinal tract, is used as potent gastroprotective antiulcer agent. The aim of this study has been the investigation of the effect of sulglycotide for the treatment of dry eye disease in a mouse model.

Methods : Dry eye was experimentally induced in NOD.B10.H2b mice through subcutaneous injections of scopolamine and exposure to an air draft for 10 days. Ten days later, the mice were treated with vehicle (n=6), 1% SOS (n = 4), 2% SOS (n = 4), 3% SOS (n = 4), 4% SOS (n = 10), cyclosporine (n=6), diquafosol (n=6), and the sodium hyaluronate group (n=6) for 10 days. We estimated the effect of SOS formulations on tear production, epithelium stabilization, mucin secretion and inflammation.

Results : The desiccation stress significantly decreased tear production and corneal epithelium stabilization. Furthermore, the desiccation stress markedly decreased the numbers of goblet cells and mucin stained cells in conjuectiva. In addition, the expression of pro-inflammatory-related factors was markedly induced by desiccation stress in the lacrimal glands. However, the topical SOS 4 eye drops not only markedly increased tear production to 0.21 ± 0.04 μL from 5 days after treatment, that similar to medicines for dry eye disease including CsA, but also the tear volume of SOS 4 group (0.25 ± 0.02 μL, p<0.05) recover to the baseline levels at 10 days after treatment. The SOS 4 eye drops effectively suppressed the corneal irregularity and epithelium detachment. In additions, the numbers of goblet cells that secrete gel-forming mucin was improved to control levels by SOS 4 treatment in conjunctiva. The topical SOS 4 significantly induced the expression of membrane-associated mucins including Muc1, Muc4 and Muc16, as well as the gel-forming mucin, Muc5AC and the efficacy was similar with CsA treatment. Furthermore, SOS formulations has been an anti-inflammatory improvements in a dose-dependent manner.

Conclusions : Overall, we suggested that a new ophthalmic pharmaceutical formulation, topical sulglycotide enhances the ocular mucin secretion in the desiccation stress-mediated dry eye disease and can be used as new biomedical material to treat dry eye disease

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×